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Traditional medicines provide fertile ground for modern drug development, but first they 
must pass along a pathway of discovery, isolation, and mechanistic studies before eventual 
deployment in the clinic. Here, we highlight the challenges along this route, focusing on the 
compounds artemisinin, triptolide, celastrol, capsaicin, and curcumin.Traditional medicines continue to 
provide front-line pharmacotherapy 
for many millions of people world-
wide. Although their application is 
often viewed with skepticism by the 
Western medical establishment, 
medicinal extracts used in ancient 
medical traditions such as Ayurveda 
on the Indian subcontinent and tra-
ditional Chinese medicine (TCM) are 
a rich source of therapeutic leads for 
the pharmaceutical industry.
The transformation of traditional 
medicines into modern drugs has its 
origins in the archetypal examples of 
the antimalarial quinine and the anti-
pyretic analgesic aspirin. The alkaloid 
quinine was isolated in 1820 from 
the bark of several species of Cin-
chona, thought to have been used by Peruvian Indians to suppress shiver-
ing and used since the 17th century 
in the treatment of malarial fevers 
(Greenwood, 1992). Similarly, aspirin 
was derived from salicylic acid in the 
bark of the willow tree (Salix species), 
used traditionally to treat fever and 
inflammation in many cultures world-
wide for at least four millennia (Mahdi 
et al., 2006). The successes of these 
two early “blockbuster” drugs set 
the stage for ongoing drug discovery 
efforts from traditional medicines.
Compounds derived from medici-
nal extracts are appealing for several 
reasons (Schmidt et al., 2007). They 
are often stereochemically complex, 
multi- or macrocyclic molecules with 
limited likelihood of prior chemi-
cal synthesis, and they tend to have Cell 130, Sepinteresting biological properties. But 
perhaps most importantly, parent 
extracts have been “clinically” tested 
in their traditional milieu, in some 
cases over millennia.
Despite these advantages, the path 
from traditional medicine to Western 
pharmaceutical is fraught with chal-
lenges. Here, we discuss the chal-
lenges of each of the four steps in this 
pipeline (see Figure 1): Western “dis-
covery” of a traditional medicine, iso-
lation and/or synthesis of the active 
component, elucidation of the molec-
ular mechanism, and development 
as a pharmaceutical. We focus on 
five interesting and timely examples 
derived from traditional medicines in 
varied therapeutic classes, each at 
a different stage in the development Figure 1. The Route from Traditional Medicine to Modern Drug
Shown are five traditional medicines—artemisinin, triptolide, celastrol, capsaicin, and curcumin—and the points in the pathway from ancient remedy 
to modern drug where they face the biggest hurdles.tember 7, 2007 ©2007 Elsevier Inc. 769
Table 1. Five Traditional Medicines in Clinical Trials
Clinical Trials
Compound Disease Number Principal Sponsors
Artemisinin Malaria 81 31 charities, institutes, universities, and companies based in Austra-
lia, Austria, Belgium, Colombia, Ethiopia, France, Gambia, Germany, 
Ghana, Guinea-Bissau, the Netherlands, Papua New Guinea, South 
Africa, Sudan, Sweden, Switzerland, the United Kingdom, and the USA; 
and working in numerous Asian, African, and South American locations
Cytomegalovirus 
infection
1 Hadassah Medical Organization, Israel
Schistosomiasis 1 Dafra Pharma, Belgium
Triptolide & Celastrol 
(T. wilfordii extract)
Rheumatoid 
 arthritis
1 National Institute of Arthritis and Musculoskeletal and Skin Diseases, 
MD, USA
Capsaicin Chronic pain 13 NeurogesX, CA, USA; AlgoRx Pharmaceuticals, NJ, USA
Postoperative pain 5 National Institute of Dental and Craniofacial Research, MD, USA;  
AlgoRx Pharmaceuticals, NJ, USA
Radiation-induced 
mucositis
1 North Central Cancer Treatment Group, MN, USA
Alopecia areata 1 University of Minnesota, USA
Morton’s neuroma 1 AlgoRx Pharmaceuticals, NJ, USA
Osteoarthritis 1 Khon Kaen University, Thailand
Interstitial cystitis 1 National Institute of Diabetes and Digestive and Kidney Diseases, MD, 
USA
Curcumin Colon cancer 6 Chao Family Comprehensive Cancer Center, CA, USA; Tel-Aviv 
Sourasky Medical Center, Israel; Johns Hopkins University, MD, USA; 
University of Michigan Comprehensive Cancer Center, USA; University 
of Pennsylvania, USA; University of Medicine and Dentistry, NJ, USA
Pancreatic cancer 3 Rambam Medical Center, Israel; M.D. Anderson Cancer Center, TX, 
USA; Tel-Aviv Sourasky Medical Center, Israel
Alzheimer’s disease 2 John Douglas French Foundation, CA, USA; Chinese University of Hong 
Kong
Chemotherapy- 
induced mucositis
1 Hadassah Medical Organization, Israel
Multiple myeloma 1 M.D. Anderson Cancer Center, TX, USA
Psoriasis 1 University of Pennsylvania, USA
Cystic fibrosis 1 Seer Pharmaceuticals, CT, USA
Includes registered, open, closed, terminated, and completed trials of these compounds, parent extracts, or derivatives. For 
details see www.clinicaltrials.gov. Data current as of August 21, 2007.process, highlighting successes and 
roadblocks on the path to status as a 
Western drug.
Artemisinin: Production Problems
The antimalarial artemisinin (and 
derivatives) represents one of the 
greatest recent clinical success sto-
ries arising from a traditional medi-
cine, echoing the success of quinine 
two centuries earlier. Artemisinin 
(see Figure 1) is derived from Arte-
misia annua L., the sweet wormwood 
(qinghao), a shrub first documented 
in TCM in 168 BCE as a hemorrhoid 
treatment (Liu et al., 2006). Since at 770 Cell 130, September 7, 2007 ©2007 least the fourth century CE, it has 
been used in the treatment of fever 
attributed to malaria. This long history 
of use prompted Chinese researchers 
to seek the active antimalarial prin-
ciple; artemisinin was isolated and 
its structure determined in the mid 
1970s (Liu et al., 2006).
Artemisinin, an endoperoxide ses-
quiterpene lactone with a complex 
polycyclic ring structure, is modified 
by Fe2+ ions to structures containing 
carbon-centered free radicals. Given 
that the intracellular environment 
of the Plasmodium malaria parasite 
is rich in this ion from heme, these Elsevier Inc.radicals are currently thought to be 
responsible for artemisinin’s antima-
larial activity. The classic method of 
cell fractionation after treatment with 
radiolabeled artemisinin has identi-
fied numerous cellular constituents 
alkylated by artemisinin (Asawamaha-
sakda et al., 1994); the strongest vali-
dated target for artemisinin is PfATP6, 
the Plasmodium sarco-endoplas-
mic reticulum Ca2+ ATPase (SERCA), 
which is inhibited by artemisinin (Eck-
stein-Ludwig et al., 2003).
Clinical studies, initiated in the 
1970s prior to any mechanistic 
insights into artemisinin function, 
demonstrated that artemisinin and 
its derivatives are powerful antima-
larials. They have proved particularly 
effective for treating severe malaria 
and, in combination with traditional 
antimalarials, for combatting Plas-
modium drug resistance. Combina-
tion therapies containing artemisinin 
are now considered the treatment 
of choice for malaria in Asia, with 
growing adoption in Africa (see Table 
1 for information on clinical trials). 
Artemisinin may also have efficacy 
against other parasites and as an 
anticancer compound, possibly act-
ing via antiangiogenic and proapop-
totic mechanisms in the latter case 
(Efferth, 2007).
Despite these dramatic findings, 
widespread deployment of artemis-
inin has been hindered by produc-
tion difficulties. Although a dozen 
synthetic routes to artemisinin have 
been described, all are complex and 
low yielding, rendering them eco-
nomically unfeasible (Liu et al., 2006). 
Synthetic chemistry has, however, 
offered semi-synthetic artemisinin 
derivatives with improved solubil-
ity (such as sodium artesunate) and 
stability (such as artemether) (Efferth, 
2007). Even a totally synthetic trioxo-
lane compound RBX11160 (OZ277), 
inspired by the trioxane endoperox-
ide moiety of artemisinin, has shown 
promise as an antimalarial (Venner-
strom et al., 2004).
Artemisinin for clinical use is pre-
dominantly produced naturally in 
A. annua plants. Despite efforts to 
maximize agricultural production, the 
artemisinin content in plant extracts 
varies widely due to environmental 
conditions: 0.01%–0.8% dry weight 
(Efferth, 2007). This in turn makes the 
drug itself expensive—particularly 
problematic for an antimalarial, which 
is needed in large quantities in many 
poorer countries. Cell and plantlet 
cultures are an appealing alterna-
tive source of this compound as 
they can be grown under much more 
closely controlled conditions than 
whole plants. Indeed, useful yields of 
the compound can be produced by 
feeding cultures artemisinin precur-
sors (Liu et al., 2006). An alternative 
approach is the genetic engineering of A. annua itself. The plant has proven 
genetically tractable: Several of the 
isoprenoid biosynthetic enzymes 
necessary for artemisinin produc-
tion have been cloned, and A. annua 
can be successfully transformed with 
Agrobacterium tumefaciens to over-
express key biosynthetic genes (Liu 
et al., 2006).
Perhaps the most promising strat-
egy is the use of microbes to produce 
artemisinin. In a triumph of genetic 
engineering, Ro et al. combined 
genetic activation of the endoge-
nous mevalonate isoprenoid synthe-
sis pathway with introduction of A. 
annua genes to produce artemisinic 
acid in the budding yeast Saccha-
romyces cerevisiae (Ro et al., 2006). 
This precursor compound, which can 
be readily converted to artemisinin 
in the laboratory, is secreted in large 
quantities from the yeast. Such cre-
ative strategies, leveraging the power 
of genetics and in vivo biochemistry, 
can provide a valuable counterpart 
to synthetic chemistry and natural 
sources in the production of natural 
product medicines.
Triptolide and Celastrol:  
Harnessing the Power of the 
Thunder God Vine
Trypterygium wilfordii Hook F., the 
“thunder god vine” (lei gong teng), 
is another TCM. This vine has been 
used traditionally for the treatment 
of arthritis and other diseases, and 
it is the source of several biologically 
active secondary metabolites (Tao 
and Lipsky, 2000). Some of its TCM 
uses might rely on the presence of 
multiple active components, and clin-
ical studies have been performed on 
extracts of the plant (Table 1), rather 
than on a single compound (Tao and 
Lipsky, 2000). However, substantial 
work has focused on two major bio-
active constituent compounds: trip-
tolide and celastrol (Figure 1).
Triptolide is a diterpenoid epoxide 
with a staggering variety of docu-
mented cellular effects. Along with 
anti-inflammatory activity, it shows 
anticancer, immunosuppressive, and 
antifertility effects (Qiu and Kao, 2003). 
It was isolated in 1972, and several 
synthetic routes have been described Cell 130, Sepsince then (Yang et al., 1998 and ref-
erences therein). Like artemisinin, 
however, triptolide is currently derived 
from its plant of origin with low yield: 
6–16 ng/g in one study (Brinker and 
Raskin, 2005). Little work has been 
done to investigate biotechnological 
routes to triptolide production, which 
are important to reduce reliance on 
the natural source. Moreover, contin-
ued development of derivatives of trip-
tolide such as the succinyl sodium salt 
PG490-88 will be valuable to improv-
ing the solubility and side-effect pro-
file of this compound (Tao and Lipsky, 
2000).
Determination of triptolide’s cellu-
lar target has proven to be an even 
greater challenge. This is not unusual: 
Many a promising therapeutic natural 
product has faltered when no clear-
cut mechanism of action could be 
identified. Although progression into 
the clinic without such knowledge is 
possible, as was the case with arte-
misinin, a solid knowledge of molec-
ular mechanism (ideally at the struc-
tural, not just the molecular, level) 
allows medicinal chemists to perform 
rational derivatization to improve 
affinity, specificity, pharmacoki-
netics, and stability. Knowledge of 
mechanism can also potentially lead 
to more specific clinical trials and, in 
cases like triptolide, completely new 
insights.
A large body of work describes 
triptolide’s inhibitory effects on tran-
scription mediated through NF-κB 
and NFAT (Qiu and Kao, 2003), but 
until recently, direct cellular targets 
were elusive. Nonetheless, careful 
cell fractionation with [3H]-triptolide 
enabled identification of the Ca2+ 
channel polycystin-2 (encoded by the 
PKD2 gene) as a possible triptolide-
binding protein (others also likely 
exist) (Leuenroth et al., 2007). PKD2 
or the gene encoding its activator, 
PKD1, causes polycystic kidney dis-
ease (PKD) when mutated because 
entry of Ca2+ ions is essential for 
growth arrest of epithelial cells form-
ing the kidney tubule. Because trip-
tolide activates opening of the poly-
cystin-2 channel, it could potentially 
complement loss of PKD1. This is the 
case in a mouse model of polycys-tember 7, 2007 ©2007 Elsevier Inc. 771
tic kidney disease in which the mice 
lack Pkd1 (Leuenroth et al., 2007). 
Thus, this calcium-dependent activ-
ity of triptolide, which is unrelated to 
its transcriptional repression activity 
(Leuenroth and Crews, 2005), opens 
a new therapeutic avenue for pursu-
ing triptolide, in addition to its effects 
on the immune and reproductive sys-
tems and in cancer.
Highlighting the complexity of 
plant extracts, the pentacyclic triter-
pene celastrol (Figure 1) is structur-
ally a very different component of T. 
wilfordii with a divergent therapeu-
tic profile. Celastrol (also known as 
tripterine) is extracted in small quan-
tities from T. wilfordii or other mem-
bers of the Celastraceae (bittersweet) 
family. To our knowledge, no total 
synthesis or alternative production 
routes have been reported.
Although not yet tested as a single 
agent in humans (Table 1), celastrol 
has shown promise as an anti-inflam-
matory compound in animal models 
of arthritis, lupus, amyotrophic lateral 
sclerosis, and Alzheimer’s disease 
(Sethi et al., 2007 and references 
therein). It also has antiproliferative 
effects against numerous cancer cell 
lines. Several molecular mechanisms 
have been identified for these effects, 
including gene expression modulation 
likely mediated through inhibition of 
NF-κB via TAK1 and IκBα kinase (Sethi 
et al., 2007 and references therein), 
proteasome inhibition, topoisomerase 
II inhibition, and heat shock response 
activation (Hieronymus et al., 2006 
and references therein). Nonethe-
less, direct targets remain elusive. 
As celastrol and triptolide move into 
human studies, it will be vital not only 
to better understand their mecha-
nisms of action but also to investigate 
any potential synergistic effects of the 
two compounds, both at the cellular 
and organismal levels.
Capsaicin: Painless for Some?
Used worldwide, the alkaloid cap-
saicin is the main cause of the “hot” 
sensation associated with chili pep-
pers, members of the genus Capsi-
cum. Beyond their widespread use 
as a spice, chili peppers were used 
in the Americas by the Aztecs and 772 Cell 130, September 7, 2007 ©2007 Tarahumara Indians as a remedy for 
coughs and bronchitis. Similar uses 
plus anti-inflammatory and gastroin-
testinal applications were adopted in 
India after the Portuguese imported 
chili peppers in the late 15th century. 
In Africa, they are traditionally used 
internally and externally as antisep-
tics (Dasgupta and Fowler, 1997). 
However, modern usage of capsaicin 
is focused on the treatment of various 
types of pain (see below) and also 
in the treatment of detrusor hyper-
reflexia, a form of urinary inconti-
nence (Dasgupta and Fowler, 1997). 
High-dose oral capsaicin also has 
anticancer properties in some animal 
model studies but seems to be a can-
cer promoter in others.
Compared with artemisinin, trip-
tolide, and celastrol, capsaicin is 
chemically quite simple (Figure 1). It 
was purified and named in the 19th 
century and first synthesized in the 
1920s (Dasgupta and Fowler, 1997). 
But the widespread cultivation of 
Capsicum makes synthesis unneces-
sary, as large quantities of capsaicin 
can easily be extracted from readily 
available peppers.
The mechanism of capsaicin in pain 
induction has been the topic of much 
neurophysiological research (Cor-
tright et al., 2007). Capsaicin, along 
with thermal heat, directly activates 
nociceptors in the skin, the sensory 
neurons responsible for the sensation 
of pain, with the subsequent release 
of the neurotransmitter substance 
P. Capsaicin’s therapeutic effect on 
pain is due to the desensitization and 
eventual destruction of nociceptors 
following repeated capsaicin expo-
sure. In a classic example of expres-
sion cloning, Caterina et al. identified 
the capsaicin receptor (Caterina et 
al., 1997). Capsaicin was known to 
cause Ca2+ ion influx into nociceptors, 
so these authors transfected a noci-
ceptor cDNA library into nonexcit-
able HEK293 cells and screened for 
capsaicin-dependent Ca2+ ion influx. 
The receptor they cloned, now known 
as TRPV1, is a Ca2+ ion channel that 
also responds to, and integrates, sig-
nals from piperine (the irritant in black 
pepper), protons, and other noxious 
stimuli (Caterina et al., 1997).Elsevier Inc.The cloning of TRPV1 kick started 
the field of pain receptor pharmacol-
ogy. Numerous pharmaceutical com-
panies are developing both TRPV1 
antagonists (to block nociception 
directly) and agonists (to desensitize 
nociceptors, as with capsaicin) (Immke 
and Gavva, 2006). Resiniferatoxin, 
another traditional medicine from the 
latex of Euphorbia resinifera, is one 
such agonist with higher potency than 
capsaicin (Immke and Gavva, 2006). 
Efforts continue to create TRPV1 ago-
nists with better skin permeation and 
lacking the distinctive side effect of a 
burning sensation on application.
Capsaicin itself has been used 
clinically with moderate success as a 
topical treatment for the pain of rheu-
matoid and osteoarthritis, psoriasis, 
diabetic neuropathy, and posther-
petic neuralgia (Table 1), but herein 
lies the particular challenge with 
this molecule: The chronic pain dis-
orders are notoriously idiosyncratic, 
and not all patients or all pain syn-
dromes respond to capsaicin (Immke 
and Gavva, 2006). The somewhat 
vague and diffuse traditional uses of 
this compound offer little assistance 
here, unlike artemisinin, for instance. 
Thus, testing for capsaicin efficacy 
is a matter of clinical trial and error, 
largely undermining the “tried and 
true” advantage of a traditional medi-
cine. The major clinical advantage 
that capsaicin holds over other unre-
lated pain drugs under development 
is its approved status as a foodstuff.
Curcumin: Awaiting Targets and 
Outcomes
Like capsaicin, the polyphenol cur-
cumin (Figure 1) is best known as a 
spice constituent: It is the yellow pig-
ment component of the curry spice 
turmeric (Curcuma longa, known as 
haldi in Hindi). It is also, however, a 
drug used in Ayurveda and TCM in 
the treatment of diseases as diverse 
as rheumatism, fever, intestinal dis-
orders, trauma, and amenorrhea (see 
the Analysis by S. Singh on page 765 
of this issue). Modern research has 
attributed anti-inflammatory, immuno-
modulatory, antimalarial, and antican-
cer effects to this multitalented com-
pound (Aggarwal et al., 2007).
Like capsaicin, synthesis of cur-
cumin is trivial and was first reported 
in 1910, but sufficient quantities of 
curcumin for therapeutic use are 
available from the spice. This is par-
ticularly important as low bioavail-
ability of the parent compound cou-
pled with rapid intestinal metabolism 
dictates large doses for clinical use 
(Sharma et al., 2005); derivatization of 
the natural product is actively being 
pursued.
Given its pleiotropic clinical effects, 
it is perhaps not surprising that cur-
cumin has documented effects on 
countless intracellular signaling path-
ways. Its anti-inflammatory action 
can be attributed largely to its inhibi-
tion of NF-κB activity, COX-2 and 5-
LOX expression, and cytokine release 
(Aggarwal et al., 2007). Curcumin 
may directly target IκBα kinase to 
block NF-κB. It also binds to a num-
ber of other proteins, including thio-
redoxin reductase, several kinases, 
and several receptors (Aggarwal et 
al., 2007). The challenge here, then, 
as with many other natural products, 
is deciphering which of these targets 
is mechanistically valid for which bio-
logical activity. With such a broad 
spectrum of potential targets and 
activities described for curcumin, this 
is no easy task. Synthesis of deriva-
tives that selectively ablate certain 
cellular and/or therapeutic effects 
is one possible route to tease apart 
this mechanism-function conun-
drum, perhaps in concert with radio-
labeled fractionation experiments (as 
described above) or affinity chroma-
tography with immobilized curcumin.
The very versatility that makes cur-
cumin appealing has also limited its 
rigorous clinical testing: There are 
wide-ranging efficacy reports, but 
most are based on preclinical, anec-
dotal, or pilot studies rather than on 
randomized, placebo-controlled, 
double-blind trials (Hsu and Cheng, 
2007). Activity has been reported in 
several inflammatory and autoim-
mune diseases and numerous can-
cers, both as a preventative agent 
and treatment, alone or in combina-
tion (Hsu and Cheng, 2007). The rela-
tive ease and rapid payoff of under-
taking preclinical or pilot studies, compared to rigorous clinical trials, 
has slowed the formal validation of 
curcumin. This is confounded by lim-
ited pharmaceutical company inter-
est because curcumin itself is not 
patentable (although synthetic meth-
ods, derivatives, and pharmaceutical 
formulations are) and by the percep-
tion that, as a foodstuff, curcumin 
is more a nutraceutical (perhaps a 
dietary cancer preventative) than a 
traditional drug. This perception can 
only be changed by clinical studies 
showing successful disease treat-
ment with curcumin. Phase I studies 
have documented tolerance up to 
8000 mg/day, allowing a large dose-
response range to be tested in phase 
II studies, several of which are under-
way for the treatment of cancer, pso-
riasis, and Alzheimer’s disease (Table 
1) (Hsu and Cheng, 2007). We must 
await the outcomes of these studies 
before curcumin can be validated as 
a pharmaceutical.
Ongoing Challenges
An effective drug should be facile and 
economical to produce and deliver, 
should display favorable absorption, 
distribution, metabolism, excretion, 
and toxicity (ADMET) characteristics, 
and should treat the targeted disease 
with specificity and efficacy. Tradi-
tional medicines, as with other natu-
ral products, can offer powerful leads 
for therapeutic development because 
(unlike synthetic libraries) they 
already have documented effects on 
the organism. However, the process 
from plant to product is a slow one. 
Despite the oft-shared limitations 
noted here, these five examples of 
traditional medicines are exceptional 
in the extent to which they have been 
studied and the success they have 
achieved in the clinic; countless other 
promising compounds wallow in 
obscurity.
The challenges are formidable (Fig-
ure 1): Ethnopharmacologists must 
identify a medicine, its uses, and 
active components. These efforts are 
urgent, as traditional knowledge—
and traditional plant species—are 
being lost at an alarming rate. Chem-
ists must then synthesize the com-
pound using a cost-effective method Cell 130, Sepor develop alternative processes 
such as cell culture or transgenesis 
to enable useful-scale production. 
Despite continuing advances in syn-
thetic chemistry, the very complex-
ity of many natural products that is 
responsible for their desirable bio-
logical function can make production 
difficult.
With a reliable supply of compound 
available, biologists can then iden-
tify and validate cellular targets and 
mechanisms of action. New tools are 
sorely needed for this particularly 
daunting challenge, such as meth-
ods that compare the phenotypic or 
gene expression profiles induced by 
a small molecule to those induced by 
known compounds (Hieronymus et 
al., 2006) or chemical enhancer/sup-
pressor screens. Development of in 
silico tools to “dock” small molecules 
with protein structures to provide 
models for testing in vitro will likely 
come into their own with advances 
in structural genomics, as sufficient 
computational power becomes avail-
able.
Ideally with a mechanism in hand, 
clinicians must then test the com-
pound in the disease of interest 
(Table 1) while keeping an open mind 
for unexpected therapeutic activities 
and working with medicinal chemists 
to produce derivatives with improved 
ADMET properties. Finally, regulatory 
approval must be obtained, as with all 
drugs. This is particularly problem-
atic if the active principle is an extract 
or mixture, rather than an isolated 
compound; the U.S. Food and Drug 
Administration has been understand-
ably reluctant to approve multiple-
agent drugs until recently (Schmidt et 
al., 2007). Only in 2006 was the first 
such drug approved: Polyphenon E 
(MediGene), a topical antiviral pre-
pared from catechins extracted from 
green tea (Camellia sinensis).
Artemisinin, triptolide, celastrol, 
capsaicin, and curcumin are “poster 
children” for the power and promise 
of turning traditional medicines into 
modern drugs. However, their stories 
highlight the ongoing interdisciplinary 
research efforts that continue to be 
necessary to realize the pharmaceuti-
cal potential of traditional therapeutics.tember 7, 2007 ©2007 Elsevier Inc. 773
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